Rhys Anderson

Cell Biologist researching senescence and ageing @KingsCollegeLon | Core @VitaDAO | Editor @longevist_xyz

[Michael Torres @Mykalt45]

@artan_bio Raises $200,000 in Decentralized Funding to Advance Longevity Science Through Mutation-Specific Codon Su... https://t.co/WHvO0iaFej

Crypto + Biotech = A real thing. Excited for $vitarna token holders. We’re going to make waves in longevity. No need for $100Ms. CrossBridge flipped the script!

[VitaDAO 💛 @vitadao]

.@Cyclarity , backed by @vitadao, presented Phase 1 results for UDP-003 at AHA Vascular Discovery.

First human evidence that 7-ketocholesterol (7KC), a driver of arterial plaque, can be safely excreted.

All endpoints met, no SAEs. Phase 2 on plaque regression in 2026.

https://t.co/VYGMRivbjo

[Michael Torres @Mykalt45]

Attention $vitarna token-holders and the DeSci: I’ve been a tad busy with my other company!

That said, we’ve been cooking quite a bit with @artan_bio and Vitarna! I hope you all are ready for the ride!

To spell it out: with CrossBridge I took a project that was in the university 3 years ago and with $10M in VC money I turned that into a $300M buyout from the world’s most valuable pharma.

We’re pushing on the same things for vitarna token-holders!

When you do it it, this can be the outcome! Going to show the world what we’re capable of!

I’ll be personally investing in Artan, too, and hope to raise through the token as well! @vitadao @vitarnabio @Molecule_sci @alxdobrin @paulkhls

[VitaDAO 💛 @vitadao]

Our March longevity newsletter is here.

• Rubedo's GPX4 modulator hits positive Phase 1 results in psoriasis and atopic dermatitis
• Cyclarity publishes landmark 7KC review, Phase 1 readout coming later this year
• Eli Lilly signs deal worth up to $2.75B with Insilico Medicine
• ARPA-H commits $144M to aging research
• VitaLabs Season 2 reviews 100+ applications from six continents

Plus portfolio updates and curated longevity science. 👇

https://t.co/MFHXUuoWPQ

[VitaDAO 💛 @vitadao]

Our February longevity newsletter is here.

• First human trial for partial epigenetic reprogramming approved
• Aubrai, built on the BioAgents framework, hits #1 on BixBench
• FOXO3 ASO project running ahead of schedule
• Rapamycin + exercise trial results accepted for publication

Plus 20+ curated papers on the science of aging. 👇

https://t.co/3WwXbWYyJ1

[VitaDAO 💛 @vitadao]

HAGR databases have been a cornerstone of aging research for two decades.

Losing them because of a funding gap would be a real setback for the field. If you've ever used these resources or care about longevity research infrastructure, take a look

[Dr Brad Stanfield @BradStanfieldMD]

It FINALLY happened!!!!
The Rapamycin & Exercise clinical trial manuscript has been accepted

5 years in the making

Special thanks to @mkaeberlein, @LifespanNews, @vitadao, everyone who donated, and viewers of my channel.

[VitaDAO 💛 @vitadao]

Fang Lab just published a peer-reviewed paper in Advanced Science.

The VitaDAO-funded project used AI-driven drug discovery to identify α-Amyrin as a mitophagy activator that reduces Tau pathology and preserves memory in Alzheimer's disease models.

https://t.co/63T3MDujSY

[Michael Torres @Mykalt45]

Attention $VITARNA token holders and all Longevity/DeSci communities:

🧬 New longevity preprint just dropped — and it quietly validates an entirely different way to think about aging:
👉 https://t.co/r5cjlvm5ZZ

This isn’t about clocks, epigenetics, or cell states.

It’s about whether cells can still read the code.
@vitadao @vitarnabio @artan_bio @Molecule_sci @paulkhls @BioProtocolEco

[VitaDAO 💛 @vitadao]

🚨LIVE NOW: VitaDAO Community Call!

Covering:

- VitaLabs S1 outcomes
- S2 announcement
- @Aubrai_ IPT updates
- Portfolio company progress
- Next VitaDAO IPT launch details On @BioProtocol

👇Jump in

[Tim Peterson @timrpeterson]

Can AI design better longevity drug combinations than humans?

That’s the question we’re testing in our Synthetic Vitality project with @VitaDAO and @Aubrai /1 of 4

[Michael Torres @Mykalt45]

You guys remember this?! We got back some initial data. We’re still QC’ing, but in the spirit of DeSci and open science to benefit $vitarna token holders, I thought I’d share a few tidbits.

[VitaDAO 💛 @vitadao]

Gero, backed by the VitaDAO community, just landed a $1B+ deal with Chugai (Roche)!

Their AI finds the root causes of age-related diseases → Chugai develops antibody drugs from these discoveries.

Big leap forward for longevity research 🧬
https://t.co/HSdz0GIqpe

[Molecule @Molecule_sci]

The lead researcher behind the VITA-FAST IPT sat down with us at the DeSci Summit in Dubai.

His mission: extend human life with cutting-edge science.

His team: @UniofNewcastle, @vitadao & his @vitafastbio IPT community.

Learn more about VITA-FAST & other active IPTs via the link in bio.

[VitaDAO 💛 @vitadao]

VitaRNA Progress Update 🧬

@vitarnabio’s ARTAN-102 gene therapy aces mouse studies:

✅ 14-day safety: zero adverse effects
✅ Hit all 6 organs (liver 350x, heart 32x, brain 4x)
✅ Targets age-related mutations

DAO→data in 2yr 🫡

⏭️Primates next, humans in 12mo

[VitaDAO 💛 @vitadao]

New in @NatureNeuro

Rubedo Life Sciences, backed by VitaDAO, demonstrates aging and injury cause neuronal senescence in dorsal root ganglia

Study shows senescent neurons drive neuropathic pain, opening new therapeutic avenues beyond steroids & opioids
https://t.co/7vSMd3LoO8

[VitaDAO 💛 @vitadao]

VitaLabs Season 2 — Call for Projects!

We’re funding bold, high-risk longevity research.

Join us to solve the toughest challenges in extending human life. Researchers keep ownership of their breakthroughs.

Ready to make history?

👉Apply now: https://t.co/AUcSIyqFQF

[VitaDAO 💛 @vitadao]

🎙️@RhysKAnderson at the Bio Agents Hackathon:

“Meet The Longevist — a curated longevity journal spotlighting top preprints.”

We're increasing curation from quarterly to monthly, and building LAIA, an AI agent to automate the process.

Check out the vita track at the Bio Agents hackathon

> Build a decentralized Knowledge Network + hypothesis engine using the hallmarks of aging — to accelerate scientific dissemination & validation through AI.

🔗 https://t.co/32ZS64M6iT

[Rhys Anderson @RhysKAnderson]

@bionicdao_ @vitadao We're designing LAIA to curate in real time, so there won't be enough time for citations to be an input. However, after surveying some key opinion leaders, the novelty of findings is going to be one of LAIA's main focuses!

[VitaDAO 💛 @vitadao]

Aging is a disease. It’s time to cure it.

VitaLabs Season 2 is here. We’re funding bold, high-risk longevity research.

Join us to solve the toughest challenges in extending human life. Researchers keep ownership of their breakthroughs.

Ready to make history?

👉Apply now: https://t.co/RNsMKBgcEc